Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 23.90% | Reduce −1.3% | 3,905,000 | $30.54 | $119M | −50,000 | +$14M |
| ETON - Eton Pharmaceuticals | 8.17% | Add +0.3% | 2,860,000 | $14.25 | $41M | +7,930 | +$4M |
| Immunome | 6.58% | Reduce −0.6% | 3,529,581 | $9.30 | $33M | −20,419 | +$9M |
| SNWV - Sanuwave Health | 6.45% | Add +0.8% | 980,000 | $32.86 | $32M | +7,998 | −$2M |
| LQDA - Liquidia | 6.18% | Add +9.5% | 2,475,000 | $12.46 | $31M | +215,000 | −$2M |
| CDXS - Codexis | 6.16% | Add +32.6% | 12,600,000 | $2.44 | $31M | +3,100,000 | +$5M |
| RYTM - Rhythm Pharmaceuticals | 6.02% | Reduce −3.1% | 475,000 | $63.19 | $30M | −15,000 | +$4M |
| TGTX - Tg Therapeutics | 3.86% | Hold | 535,000 | $35.99 | $19M | — | — |
| OCUL - Ocular Therapeutix | 2.97% | Hold | 1,595,000 | $9.28 | $15M | — | — |
| ARVN - Arvinas | 2.48% | Reduce −14.9% | 1,680,000 | $7.36 | $12M | −295,000 | −$2M |
| LRMR - Larimar Therapeutics | 2.38% | Add +114.7% | 4,110,000 | $2.89 | $12M | +2,195,923 | +$8M |
| IRON - Disc Medicine | 1.98% | Add +119.3% | 186,418 | $52.96 | $10M | +101,418 | +$6M |
| Sarepta Therapeutics | 1.71% | New | 500,000 | $17.10 | $9M | +500,000 | +$9M |
| Vigil Neurosciences | 1.59% | New | 1,000,000 | $7.95 | $8M | +1,000,000 | +$8M |
| Protara Therapeutics | 1.48% | Reduce −50.6% | 855,000 | $8.62 | $7M | −875,000 | $— |
| CGON - Cg Oncology | 1.39% | Add +62.2% | 266,000 | $26.00 | $7M | +102,012 | +$3M |
| XOMA - XOMA Del | 1.29% | Add +0.8% | 255,087 | $25.20 | $6M | +2,044 | +$1M |
| EWTX - Edgewise Therapeutics | 1.29% | Add +24.1% | 490,000 | $13.11 | $6M | +95,000 | −$2M |
| STOK - Stoke Therapeutics | 1.28% | Add +87.4% | 562,120 | $11.35 | $6M | +262,120 | +$4M |
| ANIK - Anika Therapeutics | 1.25% | Add +49.1% | 588,797 | $10.58 | $6M | +193,797 | +$293K |
| PTGX - Protagonist Therapeutics | 1.16% | Hold | 105,000 | $55.27 | $6M | — | — |
| DNA - Ginkgo Bioworks · CLASS A | 1.13% | Reduce −58.2% | 500,000 | $11.25 | $6M | −695,000 | −$1M |
| Gossamer Bio | 0.87% | Reduce −17.3% | 3,545,000 | $1.23 | $4M | −742,415 | −$356K |
| RZLT - Rezolute | 0.81% | Add +94.3% | 903,442 | $4.46 | $4M | +438,442 | +$3M |
| RVMD - Revolution Medicines | 0.77% | New | 105,000 | $36.79 | $4M | +105,000 | +$4M |
| Essa Pharma | 0.75% | Hold | 2,209,998 | $1.70 | $4M | — | — |
| Cargo Therapeutics | 0.55% | Hold | 666,503 | $4.12 | $3M | — | — |
| MBX - Mbx Biosciences | 0.55% | Reduce −4.3% | 239,319 | $11.41 | $3M | −10,681 | +$886K |
| Zymeworks | 0.53% | Add +20.0% | 210,000 | $12.55 | $3M | +35,000 | +$551K |
| ALMS - Alumis | 0.47% | New | 775,000 | $3.00 | $2M | +775,000 | +$2M |
| ZNTL - Zentalis Pharmaceuticals | 0.45% | Reduce −3.1% | 1,924,300 | $1.16 | $2M | −60,700 | −$924K |
| TRVI - Trevi Therapeutics | 0.43% | Reduce −50.9% | 390,000 | $5.47 | $2M | −405,000 | −$3M |
| RCEL - Avita Medical | 0.41% | Reduce −11.5% | 389,519 | $5.29 | $2M | −50,481 | −$2M |
| IRD - Opus Genetics | 0.23% | Add +3.8% | 1,220,000 | $0.9421 | $1M | +45,000 | −$397K |
| DERM - Journey Medical | 0.14% | Add +37.0% | 95,000 | $7.18 | $682K | +25,677 | +$273K |
| Elevation Oncology | 0.11% | New | 1,442,061 | $0.3671 | $529K | +1,442,061 | +$529K |
| IBIO — | 0.06% | Hold | 375,000 | $0.7600 | $285K | — | — |
| PEPG - Pepgen | 0.05% | Reduce −42.9% | 240,000 | $1.11 | $266K | −180,000 | −$324K |
| ADGM - Adagio Med | 0.03% | Hold | 110,571 | $1.30 | $144K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| PVLA - Palvella Therapeutics | 1.07% | Exit | 0 | $27.99 | $5M | −172,357 | −$5M |
| ANAB - Anaptys Bio | 1.04% | Exit | 0 | $18.59 | $5M | −250,933 | −$5M |
| Acelyrin | 0.89% | Exit | 0 | $2.47 | $4M | −1,615,000 | −$4M |
| Biodesix | 0.45% | Exit | 0 | $0.6251 | $2M | −3,225,000 | −$2M |
| Optinose | 0.39% | Exit | 0 | $9.17 | $2M | −193,039 | −$2M |
| Holding · CL A | 0.31% | Exit | 0 | $22.21 | $1M | −62,501 | −$1M |
| NRIX - Nurix Therapeutics | 0.30% | Exit | 0 | $11.88 | $1M | −115,000 | −$1M |
| Sangamo Therapeutics | 0.15% | Exit | 0 | $0.6559 | $692K | −1,055,000 | −$692K |
| Ventyx Biosciences | 0.05% | Exit | 0 | $1.15 | $219K | −190,000 | −$219K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2